NCL Technology Ventures
London specialist healthcare investor funding early-stage therapeutics, medtech and digital health companies
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+
- Sector focus
- Fintech, Healthtech
- Cheque size
- €1.5M–€3M
- Fund size
- Undisclosed
- Founded
- 2015
- Website
- nclim.co.uk
NCL Investment Management, the trading name of NCL Technology Ventures Ltd, is a specialist healthcare investor authorised by the Financial Conduct Authority. It provides equity and operational support to early-stage companies whose technologies aim to prevent, treat or cure disease. Areas of interest include immunology and autoimmune conditions, infectious disease, oncology, women's health and digital health. Its portfolio spans therapeutics and medtech businesses such as TC BioPharm, Centauri Therapeutics, Emteq Labs, Ampersand Health and Curesponse. Managing Partner Jerry Biggs set up the investment management business in 2015. The firm is headquartered in London, with a satellite office in New Haven, Connecticut.
← All investors · Is this your organisation? Request an update
More investors in the directory
ICONIQ Growth
San Francisco growth investor affiliated with ICONIQ Capital; co-led ElevenLabs' Series C and Motorway's Series C
General Atlantic
New York growth equity firm with USD 130bn AUM; led Flo Health's Series C and Fresha's Series C
Fidelity International
Global asset manager that also takes late-stage private stakes; invested in Gousto and Kraken Technologies
Faber
Lisbon deep tech seed fund (first tickets up to EUR 2.5m); led Biographica and co-led Ponda seed rounds
CPP Investments
Canada's national pension fund manager; growth investor in Octopus Energy and 9fin
CPI
UK deep tech innovation centre whose CPI Enterprises arm backs pre-seed and seed start-ups; backed Qualus and DEScycle
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.